Triple drug cocktail targets Hard-to-Treat colorectal cancer

NCT ID NCT06412198

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a combination of three drugs—adagrasib, cetuximab, and cemiplimab—can help control metastatic colorectal cancer in people whose tumors have a specific genetic change called KRAS G12C. About 31 adults whose cancer has not responded to at least one prior treatment will receive the drugs. The main goal is to check safety and side effects, while also seeing if the tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adagrasib, cetuximab, and cemiplimab
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific type of advanced colorectal cancer that has not responded to prior therapies.
What could go wrong: This is an early-phase trial with only 31 participants, so results may not apply broadly. The drug combination may cause significant side effects, and it is not yet known if it will effectively control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KRAS G12C MUTATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KRAS G12C MUTATIONS METASTATIC COLORECTAL CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.